Financial Performance - The company expects a net profit of between 13 million and 17 million yuan for 2024, representing a decline of 79.54% to 84.36% compared to the previous year's profit of 83.1 million yuan[3]. - The net profit after deducting non-recurring gains and losses is projected to be between 5.5 million and 8 million yuan, down 86.80% to 90.93% from 60.6 million yuan in the same period last year[3]. - In 2023, the company recorded a non-recurring gain of 17.82 million yuan from land disposal, which will not recur in the current reporting period[6]. Business Challenges - The decline in revenue is attributed to market competition and slower project progress, impacting overall business performance[5]. - The company has seen an increase in accounts receivable impairment provisions due to longer project implementation and settlement audit cycles, alongside a rise in accounts receivable balances[6]. Strategic Plans - The company plans to enhance operational capabilities, strengthen market expansion, and improve cost control to boost overall competitiveness[6]. Financial Reporting - The financial data presented is preliminary and has not been audited by the accounting firm, with final figures to be disclosed in the 2024 annual report[7].
港通医疗(301515) - 2024 Q4 - 年度业绩预告